
Mounjaro hair loss searches have more than doubled in a year
The condition, known as telogen effluvium, is a temporary form of hair loss linked to physical stress. Hair regrowth typically begins three to six months after weight loss stabilises.
'Hair loss on Mounjaro isn't typically due to the medication itself, but rather the metabolic changes that come with sudden weight loss," says Jason Murphy, Head of Pharmacy at Chemist4U.
"When people lose a significant amount of weight quickly, typically 10-20% of their body weight in just a few months, it puts the body under stress.
"That stress, combined with changes in diet and hormones, can trigger telogen effluvium.'
Telogen effluvium causes hair follicles to shift prematurely into their resting phase. Normally, most hair is actively growing, with only a small percentage resting. But when the body is under stress, a larger proportion switches to resting, leading to increased shedding two to three months later.
'This is your body's way of conserving energy during a period of change,' he says. 'Hair growth isn't essential for survival, so the body temporarily redirects energy elsewhere. It's understandably upsetting for patients, but it's actually a protective response.'
Recommended reading:
How to minimise hair loss during Mounjaro treatment
While hair shedding on Mounjaro is often temporary, it can still be distressing for those experiencing it. Fortunately, there are simple, science-backed steps that you can take to protect your hair.
1. Follow proper dose titration
"Your doctor or pharmacist will monitor your progress while you're taking Mounjaro," says Jason, an expert in weight loss injections. "Follow your prescribed schedule carefully, this is sometimes called titration, and don't try to increase your dose or lose weight too quickly. Aiming for around 1 to 2 pounds a week is much gentler on the body and can reduce how much hair you shed."
2. Prioritise protein and balanced nutrition
Protein is essential for growing healthy hair because it's the building block of new hair cells. It also helps your body produce the enzymes and hormones needed to support hair growth from the inside out. If your diet lacks essential nutrients, a daily multivitamin can help fill the gaps. Look for products with biotin, iron and zinc, as these play an important role in nourishing your hair follicles and scalp.
3. Practice gentle hair care
Avoid harsh brushing, heat styling or tight hairstyles like ponytails and braids as these can put extra stress on your hair. Use a mild shampoo that won't strip your scalp of its natural oils. Over-washing can lead to irritation, so washing two to three times a week is often enough unless you have very oily hair.
4. Support scalp health
Scalp massage can stimulate blood circulation to the scalp, improving its overall health and promoting hair regrowth. Using a massage brush or your fingertips to massage your scalp can also help distribute haircare products more evenly and make them more effective. If your hair feels dry or damaged, natural remedies like rosemary oil or black tea can help repair it at home.
5. Prioritise sleep and stress management
Stress is a well-known trigger for hair loss. To support both your mental health and hair health, build in time for rest, sleep and activities that help you manage stress, whether it's regular exercise, mindfulness or simply taking time out for yourself.
Most adults should aim for 7 to 9 hours sleep per night. This is particularly important for those experiencing hair loss, as quality sleep supports the regulation of growth hormone and tissue repair.
6. Explore topical treatments
"If you notice hair shedding while taking Mounjaro, speak to your GP or pharmacist about topical Minoxidil (Regaine for Men or Regaine for Women)," says Jason. "Minoxidil encourages blood flow to your scalp and hair follicles. This can help nutrients and oxygen flow into your hair so it grows back stronger."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Telegraph
19 minutes ago
- Telegraph
NHS to hand out more fat jabs after private clinics raise prices
The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private patients, The Telegraph can reveal. GPs are being braced for a surge in demand for the 'King Kong' of weight-loss jabs after Eli Lilly, the US pharmaceutical firm, said it would be more than doubling its prices from Sept 1. Health officials have written to family doctors about an expected increase in demand from patients who had been accessing the drug privately, but will now turn to the NHS. The Government is also looking to intervene in the dramatic price rise, it is understood, amid fears that hundreds of thousands of patients currently benefiting from losing weight on the jabs could be forced to stop taking them. Eli Lilly said it was increasing the cost of Mounjaro – also known as tirzepatide – in the UK to bring it in line with 'other developed nations'. In July, Donald Trump demanded that drug manufacturers lower their prices for American patients and stop other countries 'freeloading' off US firms. The US president previously complained that a friend had the 'fat drug' in London for a fraction of its US price despite being 'the same box made in the same plant by the same company'. Eli Lilly is increasing the wholesale price UK retailers will pay for a middle-sized 5mg dose from £92 to £180, and for the maximum dose, 15mg, from £122 to £330. These costs are likely to be passed on to private patients, of which there are almost one million taking Mounjaro, most of whom will now face the choice of paying the increased rates or stopping the drug. But the NHS has said it will continue prescriptions for patients who had been accessing the drugs privately if they meet certain criteria. The health service has a commercial deal in place to roll out the jab at a cheaper price. The cost of a prescription to patients is £9.90. A letter from NHS officials to GPs seen by The Telegraph said the NHS could continue treatment 'for people that have previously accessed tirzepatide through a private provider' if they meet eligibility criteria when assessed by a weight management service. Under current guidance, patients must have a body mass index of 40 or more 'in addition to four or more qualifying comorbidities', such as diabetes and high blood pressure, as part of a phased rollout. From next April, people with a BMI of 35 or more will also be able to get the jab on the NHS, with plans to eventually roll it out to more than three million. People accessing the anti-obesity injections privately are supposed to have a BMI of more than 30, but some people have been 'cheating the system' in order to access it, according to Wes Streeting, the Health Secretary. It is not known how many people will be eligible to move over to an NHS prescription from a private one. There were 32,000 patients waiting for an appointment at a weight management service in the community as of the end of June. While the majority of patients are being seen within 18 weeks, more than 2,000 have been waiting for more than a year. NHS officials also said GPs should tell patients asking for weight-loss jabs if they are not currently eligible. This includes those who may have started treatment with a BMI of more than 40 but is now less. 'We recognise this may be disappointing for people,' the update said, adding that doctors 'could provide reassurance to the person that stopping tirzepatide, that is being taken for its licensed weight loss indication, is not known to cause withdrawal symptoms, but that they should continue, where appropriate, a reduced-calorie diet and increased physical activity if they want to reduce the risk of weight regain'. It said anyone with questions about stopping the drugs should be directed back to their private provider. More people could also turn to the other weight-loss jab available in the UK, rival brand Wegovy, made by Danish firm Novo Nordisk. A spokesman for the company, which also makes Ozempic, said they had 'no plans of changing our offering in the UK'. 'Our focus is on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most,' they said. 'Our mission is to help create a healthier world by addressing some of the most pressing threats to public health – including obesity, diabetes and cardiovascular disease.' A Department of Health spokesman said: 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to so do in a safe and controlled way. 'Pricing in the private market is a matter for Eli Lilly and for private providers of weight loss and diabetes services. Eli Lilly are working with providers to maintain patient access. 'NHS commissioning of tirzepatide, based on clinical priority, is unaffected by the change in list price.'


The Independent
2 hours ago
- The Independent
Patients warned not to turn to fake weight loss jabs after UK Mounjaro price hike
Medical experts have warned Britons not to turn to fake weight loss jabs after fears the Mounjaro price hike could make it unaffordable for people 'already struggling to pay for it'. The cost of the drug, dubbed the 'King Kong' of weight loss medicine, is set to triple in the UK after its US -owned company equalised costs in markets across the globe. A month's supply of the highest doses of the jab will rise from £122 to £330 - an increase of 170 per cent. Though this will not affect patients prescribed the jab on the NHS, it will affect thousands of people who are currently buying the medicine privately. Professor Claire Anderson, president of the Royal Pharmacist Society (RPS), said the price hike risks rendering the jabs out of reach for people already struggling to afford them. 'It's reassuring that NHS patients with obesity and type 2 diabetes will continue to access Mounjaro,' she told The Independent. 'However, rising private prescription costs may make Mounjaro unaffordable for people in deprived areas already struggling to pay for it.' She said the RPS urges anyone considering obtaining Mounjaro to do so only from a UK pharmacy that is registered with the General Pharmaceutical Council and with a valid prescription. She warned fakes could be harmful or non-effective and said: 'Counterfeit medicines from unregulated sources pose serious health risks—they can contain incorrect doses, harmful substances or no active ingredient at all.' She added that if patients If buying online, check the site displays the official green GPhC logo linking to the GPhC register. Professor Kamila Hawthorne, Chair of the Royal College of GPs, also urged patients to only use reputable outlets and to speak with their private provider if they are concerned about potential price increases to the drug. She said: 'If they are accessing medication through dubious online sources, or without a prescription, it can be a genuine threat to a patient's safety. In some cases, people may not be buying what they think they are, which is really dangerous.' Fake jabs for sale in the UK are already a huge concern, with thousands of fraudulent online pharmacies selling such products having been uncovered. Fake versions of Ozempic, another popular brand of weight loss jab, have been found being sold for as little as £13.70 per dose, along with counterfeit versions of other brands, including Rybelsus and Metformin pills, being offered from 24p. Researchers from Avast, a cybersecurity brand of the company Gen, who conducted the investigation, warned of the 'dangerous' threat of the global scam involving more than 5,000 fake pharmacy sites this year, which they say are being run by criminal networks. It comes amid the rapid rise of weight-loss medication in the UK – with around 1.5 million people, 4 per cent of households, currently using them. These weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. In June, the NHS offered Mounjaro to obese patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market.


Scottish Sun
2 hours ago
- Scottish Sun
Rival fat jab WON'T increase in price, makers pledge – as Mounjaro set to double in costs
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) MAKERS of the fat jab Wegovy say they will not increase the price of the drug when the cost of rival Mounjaro doubles next month. A price war now looms as Danish firm Novo Nordisk said it is committed to keeping its weight loss injection affordable. Sign up for Scottish Sun newsletter Sign up 1 Wegovy is one of the two most popular weight loss injections in the UK (stock image) Credit: Reuters Slimmers suffered a hammer blow on Thursday when Mounjaro maker Eli Lilly & Co revealed it would ramp up its pharmacy charges in September. Rates first revealed by The Sun show the UK wholesale price for a month's supply of the popular 5mg dose of tirzepatide will double from £92 to £180. A prescription with private pharmacy mark-ups typically costs buyers £150 to £200 and could now surge to more than £300. The minimum 2.5mg dose will cost pharmacies £133 up from £92, with a 10mg dose rising from £107 to £255 and the maximum 15mg from £122 to £330. Patients and pharmacists were shocked by the news and warned it could drive users to the black market. Price war could shake up market Wegovy is thought to be the second most popular weight loss injection used in the UK. It could now see a boom in users as its price will become more competitive after Mounjaro's rise. Studies suggest the jab, known as semaglutide and the same as Ozempic, is not as strong as Mounjaro but is still super-effective. Wegovy currently costs between £100 and £200 per month from private online pharmacies. A Novo Nordisk spokesperson told The Sun: 'We currently have no plans of changing our offering in the UK. 'Our focus is on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most. 'Our mission is to help create a healthier world by addressing some of the most pressing threats to public health – including obesity, diabetes, and cardiovascular disease.'